trial · primary record
PDS Implant with Ranibizumab 100 mg/mL
Neovascular Age-Related Macular Degeneration
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1000 |
| Primary completion | 2029-12-31 |
| Primary endpoint | Incidence and Severity of Ocular and Systemic (Non-Ocular) Adverse Events (AEs) |
| Registry ID | NCT03683251 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:46.519Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03683251
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.